Advanced Prostate Cancer

Advanced Prostate Cancer/

USA Federal Prostate Cancer Research Funding Eliminated

The USA federal Fiscal Year (FY) 2017 Budget eliminates funding ($13.2 million) for the entire Prostate Cancer program at the Centers for Disease Control (CDC). Malecare asks for your advocacy for restoring that funding. Click here to help out The CDC has produced dynamic prostate cancer research, particularly focused on underserved populations such as African American men, and on improving doctor - patient communication. However, you should also be aware that the CDC, just like other federal agencies, follow the prostate cancer screening recommendations set forth by the U.S. Preventive Services Task Force, which recommends against PSA based screening for [...]

By | March 28th, 2016|advocacy|0 Comments

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic hormone-sensitive prostate cancer. However, many men are very afraid to have chemotherapy as there remains concerns about the toxicity (side effects) of the drug. A recent study, however, showed that the adverse events experienced by men who have early chemotherapy tends to be short-lived and [...]

ASCO Publishes Two Independent Research Programs from Malecare

Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an abstract titled, “Understanding Prostate Cancer Survivorship Relative to Co-Habitation”   ( The findings of this research contradicted the long-standing belief that men in a marriage lived longer because they were in a marriage. We concluded that we have to look for reasons unrelated to personal relationships [...]

Myriad Genetics Attempts To Deny Patients Their Personal Genetic Information

 In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes.  We all have these two genes which, when they mutate, are associated with breast, ovarian and prostate cancers. If Myriad succeeded, they would have controlled patents on these genes and could establish a monopoly on all research and testing of these genes. Myriad is now facing a lawsuit over  denying their clients access to their own genetic information.  The four plaintiffs in the action underwent genetic testing with Myriad to determine their hereditary risk [...]

Understanding the Complexity of Prostate Cancer Drug Names – Cutting Through The Confusion

As drugs are developed they are given many different names, but the drug (or treatment) is the same despite its name. For us laymen, multiple names for the same drug is confusing. So, why are there so many different names for the same thing? Drugs usually have three different names; A chemical name that relates to its molecular composition, which is often to long to use in everyday interactions. A generic name that is non proprietary or can be used by anyone and A trade name, which is a propriety name (which is owned by the drug company that owns [...]

By | May 23rd, 2016|Drugs & Treatments, Uncategorized|0 Comments